Having trouble accessing articles? Reset your cache.

MacroGenics down on detailed OS data for margetuximab

After getting a bump in May on data released ahead of ASCO, MacroGenics lost $3.13 (17%) to $15.58 on Tuesday following detailed overall survival data from the Phase III SOPHIA trial

Read the full 318 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE